ABSTRACT Previous studies have suggested that (1) nitroglycerin causes vasodilatation by interacting with sulfhydryl groups in vascular smooth muscle, thereby activating guanylate cyclase and increasing the intracellular concentration of cyclic GMP, and (2) N-acetylcysteine, a source of sulfhydryl groups, potentiates the peripheral vasodilatory effect of nitroglycerin. This study was performed to explore the influence of N-acetylcysteine on nitroglycerin-induced coronary dilatation. In 18 patients (13 men and five women, 30 to 76 years old), coronary sinus blood flow (by thermodilution) was measured before and during intracoronary administration of nitroglycerin, 25 ,g, both before and 5 min after a 15 min intravenous infusion of (1) 5% dextrose in water (n = 8, control) or (2) 100 mg/kg N-acetylcysteine (n = 10). Nitroglycerin caused no change in heart rate or systemic arterial pressure. In the control patients, coronary sinus blood flow behaved similarly during the two injections: it was 134 36 ml/min (mean ± SD) before and 183 + 50 ml/min during injection No. 1 (average increase, 49 25 ml/min; average percent increase, 38 + 21%); and it was 131 ± 34 ml/min before and 178 + 45 ml/min during injection No. 2 (average increase, 47 + 23 ml/min; average percent increase, 37 + 20%) (NS compared with injection 1). In the patients who received N-acetylcysteine, coronary sinus blood flow was 149 + 48 ml/min before and 191 + 54 ml/min during injection 1 (average increase, 42 + 15 ml/min; average percent increase, 30 + 12%) (NS compared with eight control values). After Nacetylcysteine, coronary sinus blood flow was similar before nitroglycerin (145 ± 44 ml/min), but it rose markedly with nitroglycerin (218 + 68 ml/min) (average increase, 73 + 35 ml/min; average percent increase, 50 20%) (p < .01 compared with the values obtained in the same patients during injection 1). Thus, N-acetylcysteine, a source of sulfhydryl groups, potentiates the coronary vasodilative effect of nitroglycerin.
SEVERAL STUDIES have suggested that nitroglycerin causes vasodilatation by interacting with sulfhydryl groups in vascular smooth muscle, thereby activating guanylate cyclase and increasing the intracellular concentration of cyclic GMP. [1] [2] [3] According to this hypothesis, any agent that reduces sulfhydryl group availability may diminish the vasodilatory effect of nitroglycerin; in turn, any maneuver that increases sulfhydryl group availability may augment the magnitude of nitroglycerin-induced vasodilatation. In support of this, Needleman et Supported in part by Ischemic SCOR grant HL-17669 from the National Institutes of Health, Bethesda, and by a grant from the Texas affiliate of the American Heart Association. crynic acid (which alkylates sulfhydryl groups) inhibits nitrate-induced relaxation of rabbit aortic strips, and Horowitz et al. 4 have demonstrated that Nacetylcysteine, a sulfhydryl group "donor," potentiates the peripheral hemodynamic responses to intravenous nitroglycerin. However, no previously published report has evaluated the influence of modulators of sulfhydryl group availability on the coronary vascular response to nitroglycerin. Therefore, the present study was performed to explore the effect of N-acetylcysteine on the vasodilative response to small amounts of intracoronary nitroglycerin.
Materials and methods
Patient population. The studies were performed in 18 patients (13 men and five women, 30 to 76 year old) undergoing cardiac catheterization at Parkland Memorial Hospital for the evaluation of chest pain. The protocol was approved by the THERAPY AND PREVENTION-PHARMACOLOGY agents, calcium antagonists, and long-acting nitrates) were discontinued more than 24 hr, and sublingual niroglycerin was not given for more than 4 hr before study. The experimental protocol was performed in subjects in the fasting state after premedication with 10 mg oral diazepam. All measurements were obtained before the introduction of iodinated contrast material.
Experimental protocol. A No. 8F femoral arterial sheath was inserted percutaneously, through which a No. 7F Judkins catheter was advanced to the ostium of the left coronary artery. Its position was confirmed by the occurrence of transient T wave alterations during the injection of saline. Systemic arterial pressure was measured through the sheath's side-port extension, and heart rate was determined by electrocardiographic monitoring. A thermodilution catheter (model CCS-7U-90B, Wilton Webster Laboratories, Altadena, CA) was advanced to the coronary sinus from a basilic vein, and its position was verified fluoroscopically and oximetrically. Subsequent determinations of coronary sinus blood flow were performed by the thermodilution technique.5
After catheter placement, mean systemic arterial pressure, heart rate, and coronary sinus blood flow were recorded before, during, and for 30 sec after the intracoronary administration of 25 gg nitroglycerin (in 5 ml of solution). Then, each patient was assigned to receive an intravenous infusion of (1) 200 ml 5% dextrose in water or (2) 100 mg/kg N-acetylcysteine (kindly provided by Mead-Johnson Pharmaceuticals, Evansville, IN) in 200 ml 5% dextrose in water, given over 15 min. Five minutes after the infusion was completed, values for all variables again were recorded before, during, and for 30 sec after intracoronary 25 gg nitroglycerin in an identical manner to that followed 20 min previously. Thus, in each patient, the response of mean systemic arterial pressure, heart rate, and coronary sinus blood flow to intracoronary nitroglycerin was assessed before and after (1) 5% dextrose in water (n = 8, control) or (2) 100 mg/kg N-acetylcysteine (n = 10).
Statistical analysis. All results are reported as mean + 1 SD. In each patient, the value for coronary sinus blood flow before nitroglycerin was subtracted from the value during nitroglycerin administration, yielding the net increase in coronary sinus blood flow (in ml/min). In turn, the net increase was divided by the value for coronary sinus blood flow before nitroglycerin to yield the percent increase. Changes occurring from before to after 5% dextrose in water or N-acetylcysteine within each group were evaluated with a paired t test.6 The two groups were compared with Student's t test.7 For all analyses, a p value < .05 was considered significant.
Results
Selective coronary arteriography (performed after the experimental protocol) revealed that three patients had no significant coronary artery disease (defined as .50% luminal diameter narrowing of the.large epicardial coronary arteries), six had one-vessel disease, seven had two-vessel disease, one had three-vessel involvement, and one had narrowing of the left main coronary artery (table 1) . Six patients (three controls and three to whom N-acetylcysteine was given) received oral isosorbide dinitrate, 20 to 100 mg/day in divided doses, for more than 1 week before study, whereas the other 12 had not received a long-acting nitrate preparation for more than 1 month (table 1) .
Intracoronary nitroglycerin, 25 ,ug, caused no change in heart rate or systemic arterial pressure. No patient noted angina during its administration. In the control patients, coronary sinus blood flow was 134 + 36 m/min before and 183 + 50 ml/min during the initial injection of nitroglycerin (average increase, 49 + 25 ml/min; average percent increase, 38 ± 21%). Twenty minutes later, coronary sinus blood flow was 131 + 34 ml/minute before and 178 ± 45 ml/min during nitroglycerin (average increase, 47 ± 23 ml/min; average percent increase, 37 ± 20%) (all NS compared with initial nitroglycerin administration) (table 1; figure 1 ). In those who received N-acetylcysteine, coronary sinus blood flow was 149 + 48 mllmin before and 191 + 54 ml/min during the initial nitroglycerin injection (average increase, 42 + 15 ml/min; average percent increase, 30 ± 12%). After N-acetylcysteine was given, coronary sinus blood flow was 145 + 44 ml/min before nitroglycerin (NS compared with the values obtained before the initial nitroglycerin injection). However, it rose markedly to 218 ± 68 ml/min during administration of nitroglycerin (average increase, 73 + 35 mni/min; average percent increase, 50 + 20%) (p < .01 compared with the initial nitroglycerin injection in the same group) (table 1; figure 1 ). The response of coronary sinus blood flow to nitroglycerin after N-acetylcysteine was similar in the three patients (Nos. 9, 1 1, and 18) who received oral isosorbide dinitrate until the day before study (average percent increase, 52 ± 29%) and the seven patients who had not received a long-acting nitrate for more than 1 month (average percent increase, 50 ± 18%) (NS) (table 1). If the data from patients 11 and 16 (in whom N-acetylcysteine induced the greatest augmentation of coronary sinus blood flow with nitroglycerin) are excluded, those from the remaining eight patients demonstrate that N-acetylcysteine still potentiated nitroglycerin's vasodilative effect: the average increase in coronary sinus blood flow rose from 37 ± 11 ml/min before to 58 ± 17 ml/min after N-acetylcysteine (p < .01), and the average percent increase in coronary sinus blood flow increased from 27 ± 1 1% before to 42 ± 10% after N-acetylcysteine (p < .01) (table 1) .
N-acetylcysteine produced no adverse effects.
Discussion
Nitroglycerin relieves or prevents myocardial ischemia by relaxing the smooth muscle of arteries and veins. As a result, it (1) ply by dilating the epicardial coronary arteries' I-" and by increasing collateral and subendocardial blood flow."'" Although nitroglycerin is known to exert its salutary effect by dilating coronary and peripheral vessels, the manner in which it causes such vasodilatation is not well understood. The present study was performed to explore the mechanism of nitroglycerin-induced coronary dilatation.
Several authors have provided data in support of the hypothesis that nitroglycerin causes vasodilatation by combining with available sulfhydryl groups in vascular smooth muscle, leading to the production of Snitrosothiols. In turn, these compounds activate guanylate cyclase9' 20 and increase the intracellular concentration of cyclic GMP.2'1 Of the various S-nitrosothiols, S-nitroso-cysteine is extremely effective in activating guanylate cyclase. 19 Needleman et al. ' have shown that ethacrynic acid, a sulfhydryl alkylating agent (which reduces sulfhydryl group availability), diminishes the magnitude of smooth muscle relaxation caused by nitroglycerin, and Horowitz et al. 4 have 140 demonstrated that N-acetylcysteine, a source of sulfhydryl groups, potentiates the peripheral vascular effects of nitroglycerin. Our data complement these observations, in that N-acetylcysteine potentiated the coronary vasodilative effect of a small intracoronary injection of nitroglycerin.
N-Acetylcysteine is extensively hydrolyzed to cysteine in vivo.2' It is safe and effective in the emergency treatment of acetaminophen overdose. 22 In the present study, it was administered at a dosage and rate similar to that previously described. 4' 22 As noted in these studies, a total dose of 100 mg/kg, given over 15 min, caused no change in systemic arterial pressure or heart rate, and coronary sinus blood flow was not altered (table 1) .
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